Hamps Bio Limited is a science-led, export-oriented enterprise specializing in the manufacturing of high-quality **freeze-dried ingredients** and the distribution of **pharmaceutical products**. Founded in **2007**, the company has evolved from a private entity into a listed public corporation, debuting on the **BSE SME** platform on **December 20, 2024**. With a robust portfolio of over **180 SKUs**, the company bridges the gap between advanced biotechnology and consumer wellness. --- ### Strategic Business Verticals Hamps Bio operates through two distinct divisions, leveraging a dual-track model that combines the stability of pharmaceutical distribution with the high-growth potential of the FMCG freeze-drying sector. #### 1. Pharmaceutical & Nutritional Division This segment focuses on the manufacturing and distribution of medicines and supplements tailored for medical specialists, including **Orthopedics, Gynecologists, Physicians, and Dermatologists**. * **Portfolio:** Over **100 items**. * **Dosage Forms:** Comprehensive range including **Tablets, Capsules, Softgels, Syrups, Powders, Oils, and Injectables**. * **Financial Profile:** This segment primarily accounts for the company’s **debtors and stock** in financial reporting. #### 2. FMCG & Freeze-Dried Division (Brand: 'FZYZEY') The company’s primary growth engine, focusing on the production of freeze-dried and frozen products for **B2B and B2C** markets. * **Portfolio:** Over **80 SKUs**. * **Key Categories:** Freeze-dried fruits, fruit powders, vegetables, herbs, and **Ready-to-Eat (RTE)** products. * **Distribution:** Strong digital footprint on **Amazon** and **Flipkart**, alongside traditional domestic and export channels. * **Asset Concentration:** This segment holds the majority of the company’s **fixed assets** and manufacturing infrastructure. --- ### Manufacturing Infrastructure & Sustainability The company operates two strategic industrial units in Gujarat, designed to scale production while maintaining cost efficiencies through renewable energy. | Facility | Location | Status | Key Features | | :--- | :--- | :--- | :--- | | **Unit 1** | Ankleshwar (G.I.D.C.) | Operational | Features a **350 kVA ground-mounted solar plant** to reduce grid dependency and carbon footprint. | | **Unit 2** | Bhatpore, Surat (G.I.D.C.) | **Operational April 2025** | New state-of-the-art freeze-drying facility designed to scale production capacity. | --- ### Financial Performance & Growth Metrics Hamps Bio has demonstrated consistent scaling of both top-line revenue and bottom-line profitability. The company maintains a conservative leverage profile and has received an **unmodified audit opinion** for its financial reporting. | Financial Metric | FY 2024-25 (Audited) | FY 2023-24 (Audited) | | :--- | :--- | :--- | | **Total Revenue** | **₹ 4,521.84 Lakhs** | **₹ 3,814.12 Lakhs** | | **EBITDA** | **₹ 612.45 Lakhs** | **₹ 485.30 Lakhs** | | **Profit After Tax (PAT)** | **₹ 384.12 Lakhs** | **₹ 292.15 Lakhs** | | **Earnings Per Share (EPS)** | **₹ 4.25** | **₹ 3.22** | | **Net Worth** | **₹ 2,145.60 Lakhs** | **₹ 1,761.48 Lakhs** | | **Operating Margin** | **13.5%** | **12.7%** | | **Debt-to-Equity Ratio** | **0.35** | - | **Key Financial Observations:** * **Revenue Growth:** Achieved a **Year-on-Year (YoY) growth of 18.5%**. * **Capital Efficiency:** Maintained healthy cash flows from operations to support working capital. * **IPO Success:** Issued **1,220,000 equity shares** at a premium of **Rs. 41** per share to fund expansion. --- ### Corporate Expansion & Capital Management The company is actively utilizing its public status to enhance shareholder value and expand its corporate footprint through inorganic growth and capital restructuring. * **Strategic Acquisition:** In **March 2026**, the company completed a **100% equity acquisition** of **HSDL Innovative Private Limited** for **INR 2.04 Crore**, making it a Wholly Owned Subsidiary (**WOS**). * **Bonus Issue:** In **August 2025**, the company allotted **43,56,000 bonus shares** in a **1:1 ratio** to diversify the retail shareholding base and increase liquidity. * **Capital Increase:** Authorized Share Capital was doubled from **INR 5 Crore to INR 10 Crore** in **2025** to facilitate future funding requirements. * **Specialized Financing:** Secured **INR 2 Crore** under the **National Agriculture Infra Financing Facility** specifically for machinery procurement. --- ### Future Outlook & Strategic Targets (2025-26) Management has outlined aggressive targets for the upcoming fiscal year, predicated on the stabilization of the new Bhatpore facility and increased international penetration. * **Revenue Target:** Aiming for an approximate **30% increase** in total revenue. * **Export Growth:** Projecting **30% growth** in export volumes, with a strategic focus on **North America** and the **Middle East**. * **Operational Priorities:** * Ramping up utilization at the **Unit 2** freeze-drying plant. * Capitalizing expenditures related to **product development** to ensure long-term economic benefits. * Expanding the **FZYZEY** brand into broader FMCG categories. --- ### Leadership & Governance The board is composed of industry veterans with expertise in technical innovation and international trade. * **Mr. Herrik Shah (Chairman & MD):** Leads strategic direction and international market expansion. * **Dr. Shrenik Shah (Whole Time Director):** Oversees product innovation and technical development. * **Ms. Mitali Shah (CFO):** Manages financial planning and IPO fund utilization. * **Ms. Shivali Rajpurohit (Independent Director):** Appointed in **August 2025** for a **five-year term** to strengthen corporate governance.